Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respiratory Safety of Lemborexant in Mild OSA
NCT03471871Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lemborexant in Insomnia (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Peripheral Oxygen Saturation During Total Sleep Time at Day 1 and Apnea-Hypopnea Index at Day 8. Started Feb 2018; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03471871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471871.